All In MedTech

FDA Clearance Tracker · P010029-S002

EUFLEXXA

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 20, 2005 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 20, 2005

Approved

Time to decision

15 days

Received Oct 5, 2005. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P010029-S002
Device name
EUFLEXXA
Applicant location
Parsippany, NJ
Received
Oct 5, 2005
Decided
Oct 20, 2005
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P010029

Device type

Device class
Class III

Every decision under product code MOZ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR CHANGING THE TRADE NAME O THE PRODUCT FROM NUFLEXXA TO EUFLEXXA. THE DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGIC THERAPY AND TO SIMPLE ANALGESICS (E.G., ACETAMINOPHEN).

Source documents

Other decisions for Ferring Pharmaceuticals, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.